ArticleEcancermedicalscience2025
Vanishing clear cell carcinoma of the kidney presenting with skin metastases - a case report.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is one of the common genitourinary malignancies that has an increasing incidence. RCC presents a diagnostic challenge due to its wide range of clinical manifestations, often leading to delays in diagnosis and complicating management strategies. These tumours have clear cells in 70% of cases and have a high preponderance of haematogenous metastases to distant organs such as lungs, bones and liver. Skin metastases of RCC in the absence of an obvious renal tumour are rare. We report a young woman with clear cell renal carcinoma with skin metastasis who presented with left loin pain and acute kidney injury, prompting a series of comprehensive investigations, including imaging studies and laboratory tests. Despite these efforts, a primary tumour remained elusive. However, a breakthrough occurred when histopathological examination of a skin nodule biopsy, alongside cytological analysis of nephrostomy fluid, ultimately identified the underlying cause as malignant RCC. Despite commencing palliative Sunitinib therapy based on intermediate risk criteria, the patient died from lung metastases after 6 months of systemic medication. Here is a more succinct version. This case report emphasises the need to investigate renal primaries in unknown-origin metastases and the importance of a thorough diagnostic approach for RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.